0000899866-17-000025.txt : 20170208 0000899866-17-000025.hdr.sgml : 20170208 20170208163910 ACCESSION NUMBER: 0000899866-17-000025 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170206 FILED AS OF DATE: 20170208 DATE AS OF CHANGE: 20170208 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALEXION PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000899866 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133648318 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 COLLEGE STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 BUSINESS PHONE: 2032722596 MAIL ADDRESS: STREET 1: 100 COLLEGE STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MACKAY MARTIN CENTRAL INDEX KEY: 0001414815 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-27756 FILM NUMBER: 17583059 MAIL ADDRESS: STREET 1: PFIZER INC ATTN CORPORATE SECRETARY STREET 2: 235 EAST 42ND STREET CITY: NEW YORK STATE: NY ZIP: 10017 4 1 wf-form4_148658993769140.xml FORM 4 X0306 4 2017-02-06 0 0000899866 ALEXION PHARMACEUTICALS INC ALXN 0001414815 MACKAY MARTIN C/O ALEXION PHARMACEUTICALS, INC 100 COLLEGE STREET NEW HAVEN CT 06510 0 1 0 0 EVP & Global Head of R&D Common Stock, par value $.0001 per share 2017-02-06 4 S 0 2710 125.69 D 39978 D Common Stock, par value $.0001 per share 2017-02-06 4 S 0 18 126.88 D 39960 D This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $125.00 - $125.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $126.00 - $126.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. /s/ Michael Greco, Attorney-in-Fact for Martin Mackay 2017-02-08